{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:41:41Z","timestamp":1780339301319,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T00:00:00Z","timestamp":1499385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s13318-017-0428-8","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T13:01:43Z","timestamp":1499432503000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetic Interactions and Safety of Coadministration of Glecaprevir and Pibrentasvir in Healthy Volunteers"],"prefix":"10.1007","volume":"43","author":[{"given":"Chih-Wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armen","family":"Asatryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,7]]},"reference":[{"key":"428_CR1","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org."},{"key":"428_CR2","unstructured":"European Association for the Study of the Liver. Recommendations on Treatment of Hepatitis C. 2015. http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/recommendations-on-treatment-of-hepatitis-c-2015\/report\/1."},{"key":"428_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1227","author":"M Martinello","year":"2016","unstructured":"Martinello M, Dore GJ. Interferon-free hepatitis C treatment efficacy from clinical trials will translate to \u201creal world\u201d outcomes. Clin Infect Dis. 2016. doi:10.1093\/cid\/civ1227.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"428_CR4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/MEG.0000000000000152","volume":"26","author":"JC Lauffenburger","year":"2014","unstructured":"Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur J Gastroenterol Hepatol. 2014;26(10):1073\u201382. doi:10.1097\/meg.0000000000000152.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"428_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"C H\u00f6ner zu Siederdissen","year":"2016","unstructured":"H\u00f6ner zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug\u2013drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561\u20137. doi:10.1093\/cid\/civ973.","journal-title":"Clin Infect Dis"},{"key":"428_CR6","unstructured":"Ng T, Reisch T, Middleton T, McDaniel K, Kempf D, Lu L et al. ABT-493, a potent HCV NS3\/4A protease inhibitor with broad genotype coverage. 2014. http:\/\/www.natap.org\/2014\/CROI\/croi_14.htm. 21st Conference on Retroviruses and Opportunistic Infections, Boston."},{"key":"428_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02264-15","author":"EJ Lawitz","year":"2015","unstructured":"Lawitz EJ, O\u2019Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, et al. Potent antiviral activity of direct-acting antivirals, ABT-493 and ABT-530, with 3-day monotherapy for hepatitis C genotype 1 infection. Antimicrob Agents Chemother. 2015. doi:10.1128\/aac.02264-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"428_CR8","doi-asserted-by":"crossref","unstructured":"Poordad F, Kwo P, Hassanein T, Asatryan A, Wang S, Wyles D et al. High SVR rates with ABT-493\u00a0+\u00a0ABT-530 in non-cirrhotic patients with HCV genotypes 1, 2, 3 infection. (APASL) 25th Conference of the Asian Pacific Association for the Study of the Liver, Tokyo. 2016. http:\/\/www.natap.org\/2016\/APASL\/APASL_02.htm.","DOI":"10.1016\/S0168-8278(16)01497-5"},{"key":"428_CR9","unstructured":"Lalezari J, Gane E, Greenbloom S, Hassaein T, Asatryan A, Ng T et al. 100% SVR4 and favorable safety of ABT-493\u00a0+\u00a0ABT-530 administered for 12\u00a0weeks in non-cirrhotic patients with genotypes 4, 5 or 6 infection (SURVEYOR-I). The International Liver Congress 51st Annual Meeting, Barcelona. 2016."},{"key":"428_CR10","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/S0168-8278(16)01668-8","volume":"64","author":"F Poordad","year":"2016","unstructured":"Poordad F, Gordon SC, Asatryan A, Felizarta F, Reindollar RW, Landis C, et al. High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I study. J Hepatol. 2016;64:S160.","journal-title":"J Hepatol."},{"key":"428_CR11","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.1016\/S0168-8278(16)01700-1","volume":"64","author":"AJ Muir","year":"2016","unstructured":"Muir AJ, Strasser S, Wang S, Shafran S, Bonacini M, Kwo P, et al. High SVR rates with ABT-493\u00a0+\u00a0ABT-530 co-administered for 8\u00a0weeks in non-cirrhotic patients with HCV genotype 3 infection. J Hepatol. 2016;64:S186.","journal-title":"J Hepatol."},{"key":"428_CR12","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/S0168-8278(16)00170-7","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo P, Wyles D, Wang S, Poordad F, Gane E, Maliakkal B, et al. 100% SVR4 with ABT-493 AND ABT-530 with or without ribavirin in treatment-na\u00efve HCV genotype 3-infected patients with cirrhosis. J Hepatol. 2016;64:S208.","journal-title":"J Hepatol."},{"issue":"2","key":"428_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.xphs.2016.10.007","volume":"106","author":"CW Lin","year":"2017","unstructured":"Lin CW, Dutta S, Asatryan A, Chiu YL, Wang H, Clifton J 2nd, et al. Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a First-In-Human Study. J Pharm Sci. 2017;106(2):645\u201351. doi:10.1016\/j.xphs.2016.10.007.","journal-title":"J Pharm Sci"},{"key":"428_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.350","author":"CW Lin","year":"2017","unstructured":"Lin CW, Dutta S, Asatryan A, Wang H, Clifton J 2nd, Campbell A, et al. Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a First-in-Human Study. Clin Pharmacol Drug Dev. 2017. doi:10.1002\/cpdd.350.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"428_CR15","doi-asserted-by":"crossref","unstructured":"Kosloski M, Dutta S, Zhao W, Pugatch D, Mensa F, Kort J et al. Pharmacokinetics, safety, and tolerability of next generation direct acting antivirals ABT-493 and ABT-530 in subjects with renal impairment. 2016. http:\/\/www.natap.org\/2016\/EASL\/EASL_144.htm. The International Liver Congress, Barcelona.","DOI":"10.1016\/S0168-8278(16)00644-9"},{"key":"428_CR16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.020","author":"E Gane","year":"2016","unstructured":"Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezari J, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology. 2016. doi:10.1053\/j.gastro.2016.07.020.","journal-title":"Gastroenterology"},{"key":"428_CR17","first-page":"S768","volume":"64","author":"F Poordad","year":"2016","unstructured":"Poordad F, Felizarta F, Wang S, Asatryan A, Hassaein T, Aguilar H, et al. High SVR rates with the combination of ABT-493\u00a0+\u00a0ABT-530 for 8\u00a0weeks in non-cirrhotic patients with HCV genotype 1 or 2 infection. J Hepatol. 2016;64:S768.","journal-title":"J Hepatol"},{"key":"428_CR18","first-page":"S758","volume":"64","author":"E Gane","year":"2016","unstructured":"Gane E, Lalezari J, Asatryan A, Greenbloom S, Hassaein T, Ng T, et al. 100% SVR4 and favorable safety of ABT-493\u00a0+\u00a0ABT-530 administered for 12\u00a0weeks in non-cirrhotic patients with genotypes 4, 5, or 6 infection (SURVEYOR-I). J Hepatol. 2016;64:S758.","journal-title":"J Hepatol"},{"key":"428_CR19","doi-asserted-by":"publisher","first-page":"S809","DOI":"10.1016\/S0168-8278(16)01579-8","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo P, Poordad F, Porcalla A, Gane E, Lalezari J, Wyles D, et al. Safety of ABT-493\u00a0+\u00a0ABT-530 co-administered in patients with HCV genotype 1\u20136 infection: results from the SURVEYOR-I and SURVEYOR-II studies. J Hepatol. 2016;64:S809.","journal-title":"J Hepatol"},{"issue":"2","key":"428_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/cpt.206","volume":"99","author":"J Snoeys","year":"2016","unstructured":"Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S. Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: a PBPK-guided drug development approach. Clin Pharmacol Ther. 2016;99(2):224\u201334. doi:10.1002\/cpt.206.","journal-title":"Clin Pharmacol Ther"},{"key":"428_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0385-4","author":"AR Polepally","year":"2016","unstructured":"Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, et al. Dose- and formulation-dependent non-linear pharmacokinetic model of paritaprevir, a protease inhibitor for the treatment of hepatitis C virus infection: combined analysis from 12 phase I studies. Clin Pharmacokinet. 2016. doi:10.1007\/s40262-016-0385-4.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"428_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1517\/17425255.2016.1148685","volume":"12","author":"N Sulejmani","year":"2016","unstructured":"Sulejmani N, Jafri SM, Gordon SC. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. Expert Opin Drug Metab Toxicol. 2016;12(3):353\u201361. doi:10.1517\/17425255.2016.1148685.","journal-title":"Expert Opin Drug Metab Toxicol."},{"issue":"5","key":"428_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/bcp.12873","volume":"81","author":"RM Menon","year":"2016","unstructured":"Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol. 2016;81(5):929\u201340. doi:10.1111\/bcp.12873.","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-017-0428-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:27:48Z","timestamp":1659097668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-017-0428-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1007\/s13318-017-0428-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,7]]},"assertion":[{"value":"7 July 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The study was sponsored by AbbVie. AbbVie contributed to the study design, research, and interpretation of data, and the writing, reviewing, and approving of the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CL, WZ, AA, AC, and WL are employees of AbbVie and may hold AbbVie stock or stock options. SD is a former employee of AbbVie and may hold AbbVie stock or stock options. Medical writing support was provided by Allison Kitten and Amy Rohrlack, employees of AbbVie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.\u00a0The study protocol was approved by the institutional review board (Vista Medical Center East Institutional Review Board, Waukegan, IL, USA).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}